Arabinogalactan Astringency Reduction for Polyphenol-Rich Oral Products
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Beverages and medicaments containing high concentrations of polyphenols often exhibit excessive astringency, causing discomfort and disgust, and existing solutions are inadequate in effectively reducing this sensation.
Innovation Solution
An astringency reducing agent comprising arabinogalactan with a molecular weight of 10,000 to 1,000,000 and a 1,3-bound galactose ratio of 12 mol% or more, derived from plants like pear, green coffee, or radish, is blended into oral products to mitigate astringency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentration of polyphenol is used in beverages, then antioxidant action is improved, but astringency increases causing discomfort
Solution Approach 1:
The patent introduces arabinogalactan as an intermediary substance that mediates between polyphenol and the human body. The arabinogalactan binds to polyphenol through its specific 1,3-bound galactose structure, forming a complex that reduces astringency while preserving antioxidant activity. This intermediary approach allows the beneficial effects of polyphenol to be maintained without the harmful astringent sensation.
Solution Approach 2:
The patent changes the physical and chemical parameters of the polysaccharide structure by specifying a molecular weight of 10,000 to 1,000,000 and a 1,3-bound galactose ratio of 12 mol% or more. These parameter changes create an optimal structure for reducing astringency while maintaining antioxidant efficacy, transforming the polysaccharide from a generic component into a functional astringency-reducing agent.
2Object-affected harmful factors
If conventional astringency reducing agents like gum arabic are used, then astringency is reduced, but manufacturing complexity increases due to specific composition requirements
Solution Approach 1:
The patent applies local quality by specifying a particular structural characteristic (1,3-bound galactose) within the polysaccharide molecule rather than requiring complex overall composition. By focusing on this specific local structural feature with a ratio of 12 mol% or more, the patent simplifies manufacturing compared to conventional agents like gum arabic that require precise control of multiple compositional parameters including protein content and various sugar ratios.
Data Source
AI summary
An astringency reducing agent including an arabinogalactan which has a molecular weight of from 10,000 to 1,000,000 and a ratio of 1,3-bound galactose to total galactose of 12 mol % or more, as an active ingredient. A method for reducing astringency, including blending the astringency reducing agent into an oral product including an astringent substance.